Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal...

Descripción completa

Detalles Bibliográficos
Autores principales: Giordano, Guido, Parcesepe, Pietro, Bruno, Giuseppina, Piscazzi, Annamaria, Lizzi, Vincenzo, Remo, Andrea, Pancione, Massimo, D’Andrea, Mario Rosario, De Santis, Elena, Coppola, Luigi, Pietrafesa, Michele, Fersini, Alberto, Ambrosi, Antonio, Landriscina, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307359/
https://www.ncbi.nlm.nih.gov/pubmed/34299337
http://dx.doi.org/10.3390/ijms22147717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307359/
https://www.ncbi.nlm.nih.gov/pubmed/34299337
http://dx.doi.org/10.3390/ijms22147717

Ejemplares similares